Exelixis (EXEL) Operating Income Growth (1y) (2011 - 2026)

Exelixis (EXEL) Operating Income Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -24.89%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 2,150.96%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 80.62%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 8.65%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 145.20%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Exelixis 14.44 Bn 13.66 Bn 590.86 Mn 34.51%

Historic Data

Download Data
DateValue
Apr 3, 2026 34.51%
Jan 2, 2026 44.12%
Oct 3, 2025 73.83%
Jul 4, 2025 -22.58%
Apr 4, 2025 534.24%
Jan 3, 2025 99.55%
Sep 27, 2024 873.90%
Jun 28, 2024 254.37%
Mar 29, 2024 2.19%
Dec 29, 2023 270.12%
Sep 29, 2023 -121.28%
Jun 30, 2023 -7.00%
Mar 31, 2023 -65.37%
Sep 30, 2022 60.04%
Jul 1, 2022 -31.95%
Apr 1, 2022 1,906.88%
Oct 1, 2021 221.23%
Jul 2, 2021 62.85%
Apr 2, 2021 -108.72%
Jan 1, 2021 -68.57%